nytimes July 8, 2021 6:01pm In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug #alzheimersdisease #labelingandlabelsproduct #aduhelmdrug #drugspharmaceuticals #clinicaltrials #foodanddrugadministration #biogeninc #science #news In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. Now it recommends that the drug be given only to those with mild symptoms.
There are no comments yet.